Physician profile
Javier M Prado
NPI 1922148253
$1,524.79
in general payments reported to CMS, 2019-2025
20 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $15.75 · 2021: $45.41 · 2022: $87.17 · 2023: $179 · 2024: $531 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $693.47 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $185.44 | 2019-2025 | Invega Sustenna |
| Abbvie INC. | $82.76 | 2019 | |
| Collegium Pharmaceutical, INC. | $77.13 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $60.90 | 2025 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $56.62 | 2024 | |
| Alkermes, INC. | $55.06 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $50.05 | 2024-2025 | Rexulti |
| Lundbeck LLC | $44.95 | 2024-2025 | Rexulti |
| Corium, LLC | $36.29 | 2022-2023 | Azstarys |
| Hologic Sales and Service, LLC | $32.40 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Astrazeneca Pharmaceuticals LP | $24.52 | 2024 | Farxiga |
| Vanda Pharmaceuticals INC. | $24.51 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $17.46 | 2019 | |
| Tris Pharma INC | $15.75 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.44 | 2025 | Caplyta |
| Therapeuticsmd, INC. | $13.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.35 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.13 | 2024 | Relexxii |
| Neurocrine Biosciences, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.